These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31105061)

  • 1. Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy.
    Tong W; Maira M; Roychoudhury R; Galan A; Brahimi F; Gilbert M; Cunningham AM; Josephy S; Pirvulescu I; Moffett S; Saragovi HU
    Cell Chem Biol; 2019 Jul; 26(7):1013-1026.e4. PubMed ID: 31105061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.
    Wondimu A; Zhang T; Kieber-Emmons T; Gimotty P; Sproesser K; Somasundaram R; Ferrone S; Tsao CY; Herlyn D
    Cancer Immunol Immunother; 2008 Jul; 57(7):1079-89. PubMed ID: 18157673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside.
    Basak S; Birebent B; Purev E; Somasundaram R; Maruyama H; Zaloudik J; Swoboda R; Strittmatter W; Li W; Luckenbach A; Song H; Li J; Sproesser K; Guerry D; Nair S; Furukawa K; Herlyn D
    Cancer Immunol Immunother; 2003 Mar; 52(3):145-54. PubMed ID: 12649743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbohydrate antigens as targets for active specific immunotherapy.
    Ragupathi G
    Cancer Immunol Immunother; 1996 Nov; 43(3):152-7. PubMed ID: 9001568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer.
    Williams BB; Wall M; Miao RY; Williams B; Bertoncello I; Kershaw MH; Mantamadiotis T; Haber M; Norris MD; Gautam A; Darcy PK; Ramsay RG
    Cancer Immunol Immunother; 2008 Nov; 57(11):1635-45. PubMed ID: 18386000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells.
    Wierzbicki A; Gil M; Ciesielski M; Fenstermaker RA; Kaneko Y; Rokita H; Lau JT; Kozbor D
    J Immunol; 2008 Nov; 181(9):6644-53. PubMed ID: 18941255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.
    Zhang H; Zhang S; Cheung NK; Ragupathi G; Livingston PO
    Cancer Res; 1998 Jul; 58(13):2844-9. PubMed ID: 9661900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine.
    Bhattachary-Chatterjee M; Nath Baral R; Chatterjee SK; Das R; Zeytin H; Chakraborty M; Foon KA
    Cancer Immunol Immunother; 2000 Jun; 49(3):133-41. PubMed ID: 10881692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
    Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
    Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.
    Riemer AB; Förster-Waldl E; Brämswig KH; Pollak A; Zielinski CC; Pehamberger H; Lode HN; Scheiner O; Jensen-Jarolim E
    Eur J Immunol; 2006 May; 36(5):1267-74. PubMed ID: 16568495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of minimal tumor burden on antibody response to vaccination.
    Kim SK; Wu X; Ragupathi G; Gathuru J; Koide F; Cheung NK; Panageas K; Livingston PO
    Cancer Immunol Immunother; 2011 May; 60(5):621-7. PubMed ID: 21267719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GD3-reactive antibodies can inhibit the lysis of autologous tumor cells by tumor-infiltrating lymphocytes.
    Reilly EB; Antognetti G
    Cancer Immunol Immunother; 1992; 35(1):59-62. PubMed ID: 1611624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
    Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
    Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
    Duperret EK; Trautz A; Ammons D; Perales-Puchalt A; Wise MC; Yan J; Reed C; Weiner DB
    Clin Cancer Res; 2018 Mar; 24(5):1190-1201. PubMed ID: 29269377
    [No Abstract]   [Full Text] [Related]  

  • 16. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
    Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
    Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes.
    Bettahi I; Dasgupta G; Renaudet O; Chentoufi AA; Zhang X; Carpenter D; Yoon S; Dumy P; BenMohamed L
    Cancer Immunol Immunother; 2009 Feb; 58(2):187-200. PubMed ID: 18584174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
    Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
    Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.
    Durrant LG; Noble P; Spendlove I
    Clin Exp Immunol; 2012 Feb; 167(2):206-15. PubMed ID: 22235996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.